BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18989118)

  • 1. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
    Omuro AM; Delattre JY
    Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
    Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
    Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
    de Groot JF; Yung WK
    Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
    Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
    Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
    Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
    J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 10. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
    Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
    Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
    J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
    Jakobsen JN; Hasselbalch B; Stockhausen MT; Lassen U; Poulsen HS
    Expert Opin Pharmacother; 2011 Apr; 12(5):825-33. PubMed ID: 21385110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I inhibitors for the treatment of brain tumors.
    Feun L; Savaraj N
    Expert Rev Anticancer Ther; 2008 May; 8(5):707-16. PubMed ID: 18471044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
    Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
    Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
    Paldino MJ; Desjardins A; Friedman HS; Vredenburgh JJ; Barboriak DP
    Br J Radiol; 2012 Apr; 85(1012):382-9. PubMed ID: 21224297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.